KQ Labs is an intensive accelerator programme offered to high growth potential startup teams in the area of data-driven biomedical science.
Startups with the potential to make an impact on global health outcomes have access to unrivalled support and resources. Successful applicants are provided with a £40k award to get their startup to the next stage. The programme includes pre-accelerator, accelerator and post-accelerator activities and is run by the Crick and a number of world-leading partners with funding from Wellcome.
The 16-week KQ Labs accelerator offers startup founders access to capital and other vital resources. Its helps early-stage data-driven startup founders to validate their ideas and put their startups on a path to receive further investment from Government grants, venture capital and other sources.
All selected startup teams have access to a network of global experts in all aspects of entrepreneurship, health sector knowledge, data science and investment strategies. This network provides workshops and mentoring to support the cohort, helping them to maximise opportunities and address challenges.
The KQ Programme
- Product management
- Protecting intellectual property
- Basic and advanced funding
- Legal and regulatory requirements
- Data accessibility and ethics
- Grant funding and application advice
- Market access (UK and International)
- Leadership and team building
- Pitch training
If you would like to mentor a member of the current cohort, or if you would like to be involved in the KQ Labs in the future, please contact email@example.com.
Find out more about the previous cohorts of KQ Labs start-ups on our alumni page.
Meet the current cohort
Baseimmune is a company created to offer data-driven solutions to vaccine design. Our mission is to monitor and integrate big-data on genomics, proteomics, as well as geographical and clinical data into the antigen discovery and vaccine development pipeline.
Bold Health is a digital therapeutic platform leveraging behavioural medicine and data science to create personalised care programs for the self-management of chronic digestive conditions, starting with irritable bowel syndrome.
Imera uses machine learning to support radiologists to identify fractures in patients more effectively.
Jiva.ai is a machine learning platform that puts model integration at the centre of its data science workflow and is currently engaged in identification and diagnosis of prostate cancer from MRI scans.
My Personal Therapeutics identifies highly precise combinations of FDA-approved drugs to target an individual patient’s tumour. Our personalised cancer therapeutics technology, the Personal Discovery Process, was developed Mt Sinai Medical Center in New York.
Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. We utilise the platform to identify first-in-class drug targets and then develop drugs that modulate the identified targets.
Pexxi is a precision medicine platform, matching women with the optimal oral contraceptives based on their medical history, hormone levels and genetic profile.
PharmEnable explores new areas of the chemical space that no one else is currently searching to enable the development of vital new medicines.
Sano Genetics is a platform for personalised medicine that connects people with relevant research studies and clinical trials based on their genetic and health data.
Zetta Genomics provides the big data foundation for generation genome. Our distributed storage and analysis technology provides the quality and convenience needed to move genomics from research to medicine at scale.